ADC Therapeutics ADCT 深 沪
等待开盘 10-15 09:30:00 美东时间
1.45
-0.250
-14.71%
华盛通- 最 高1.725
- 今 开1.67
- 成交量 174.19万股
- 最 低 1.40
- 昨 收 1.70
- 总市值 1.85亿
- 52周最高 4.98
- 市盈率 静 --
- 换手率 1.36%
- 52周最低 0.7796
- 委 比 -22.71%
- 总股本 1.28亿
- 历史最高 56.59
- 量 比 0.57
- 振 幅 19.12%
- 历史最低 0.3599
- 每 手 1
- 风险率 1.34%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多ADC Therapeutics undergoes strategic financial restructuring
ADC Therapeutics (ADCT) said it is undergoing a strategic financial restructuring that includes an $86.6M private placement. The restructuring is projected to extend the company's cash runway into 20...
10-08 23:23
ADC Therapeutics Announces $86.6M Pipe Financing For 12.9M Shares At $1.42/Share And Warrants To Purchase 48.1M Shares At $1.32/Warrant; Secures Loan And Royalty Amendments
ADC Therapeutics has entered into securities purchase agreements for the sale of its equity securities to certain institutional investors, including new investor Bain Capital Life Sciences and existing investors Redmile, TCGX, and Nantahala Capital, in an $86.6 million private investment in public e...
10-08 21:07
ADC Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure Improvements
$86.6 Million Private Placement announced, with participation from new and existing investors, extending expected cash runway into 2029 HealthCare Royalty financing agreement amended, remov...
10-08 21:00
美股大行评级 | 潜在涨幅455.56%！Cardiol Therapeutics获Canaccord Genuity上调目标价至10美元，维持"买入"评级
今日重点评级关注：Canaccord Genuity：维持Cardiol Therapeutics"买入"评级，目标价从8美元升至10美元；B. Riley证券：维持Macrogenics"买入"评级，目标价从9美元升至11美元
08-18 11:39
Guggenheim Maintains Buy on ADC Therapeutics, Lowers Price Target to $5
Guggenheim analyst Michael Schmidt maintains ADC Therapeutics (NYSE:ADCT) with a Buy and lowers the price target from $10 to $5.
08-17 21:41
ADC Therapeutics shares are trading lower after the company reported mixed Q2 financial results.
ADC Therapeutics shares are trading lower after the company reported mixed Q2 financial results.
08-14 02:14
ADC Therapeutics Q2 Adj. EPS $(0.11) Beats $(0.21) Estimate, Sales $19.248M Miss $19.376M Estimate
ADC Therapeutics (NYSE:ADCT) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.21) by 47.62 percent. This is a 56 percent increase over losses of $(0.25) per share from the same period last year. The company reported quarterly sales of $19.248 million wh...
08-13 19:33
ADC Therapeutics Q2 Earnings Preview
ADC Therapeutics (ADCT) is scheduled to announce Q2 earnings results on Thursday, August 13th, before market open. The consensus EPS Estimate is -$0.22 (+12.0% Y/Y) and the consensus Revenue Estimate ...
08-13 03:06
These 7 Small Caps Are on Fire as the Second Half Begins: Here’s Why
The Russell 2000 opened the second half of 2026 pinned near a record around 3,000, going almost nowhere since the first half closed. Underneath that flat tape, seven small caps ripped 28% or more in just four trading sessions. The index, as tracked by the iShares Russell 2000 ETF (NYSE:IWM), is comi...
07-22 03:52
ADC Therapeutics Halts LOTIS-10 Liver-Impairment Study: What It Means for Zynlonta and Investors
ADC Therapeutics Ltd ($ADCT) announced an update on their ongoing clinical stud...
07-21 00:30
